EpiAxis Therapeutics announces new Board member
EpiAxis Therapeutics is pleased to announce the appointment of Rob McInnes as a non-executive director to the EpiAxis Board, following a successful fund raise supported by Sydney Angels. McInnes is one of Australia’s leading biotech IP specialists having initially...
EpiAxis announces the appointment of three new directors
EpiAxis Therapeutics has appointed Professor Pamela Munster, a highly regarded medical oncologist in the field of metastatic breast cancer and epigenetics; Keir J Loiacono, an oncology focused business development executive and intellectual property specialist; and Dr...
EpiAxis appoints Sage Group to lead global partner search
EpiAxis has appointed The Sage Group to lead the search for a global strategic partner with whom it can collaborate to exploit its new family of oncology drugs. EpiAxis Therapeutics is a rapidly growing, Australian-based pharmaceutical discovery company leading the...
There is currently no therapy to fight recurrent, metastatic breast cancer, which is the major source of death in women with breast cancer. Furthermore, current first-line treatments have extensive side-effects.We are determined to fix that.
Professor Sudha Rao
Founder at EpiAxis Therapeutics